April 26, 2024
Market Now
Intronbio inks US$667m license deal
[DISCLOSURE] IntRon Biotechnology (048530) announced on Nov. 20 that it has signed a US$667.5 million contract with Pharmavant 1 to license out technologies for novel superbacterial bio drug candidate SAL200.
By Hwang You-mee (glamazon@heraldcorp.com)
By Hwang You-mee (glamazon@heraldcorp.com)
![[KH Explains] Korean shipbuilding stocks rally: Real growth or bubble?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2024/04/25/20240425050656_0.jpg)
![[Hello India] Hyundai Motor vows to boost 'clean mobility' in India](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2024/04/25/20240425050672_0.jpg)
